#ADA25: Vertex’s diabetes cell therapy allows 10 patients to come off insulinnews2025-06-20T23:15:41+00:00June 20th, 2025|Endpoints News|
BioNTech drops indications, stops making cell therapy at Maryland sitenews2025-06-18T15:25:03+00:00June 18th, 2025|Endpoints News|
#EHA25: Gilead, Arcellx continue to tout safety of multiple myeloma cell therapy anito-celnews2025-06-16T08:48:16+00:00June 16th, 2025|Endpoints News|
Sarepta halts Duchenne gene therapy in some patients after second deathnews2025-06-16T02:18:20+00:00June 16th, 2025|Endpoints News|
SpliceBio gets $135M shortly after starting first clinical trialnews2025-06-11T07:00:58+00:00June 11th, 2025|Endpoints News|
Vertex lays off 125 workers after type 1 diabetes cell therapy failed study in Marchnews2025-06-11T01:06:41+00:00June 11th, 2025|Endpoints News|
Makary looks at ways to speed FDA approvals, talks about cutting user feesnews2025-06-05T18:38:48+00:00June 5th, 2025|Endpoints News|
Trump health appointees pledge support for cell and gene therapies at FDAnews2025-06-05T17:54:23+00:00June 5th, 2025|Endpoints News|
Regenxbio reports Duchenne gene therapy data from five patientsnews2025-06-05T14:35:07+00:00June 5th, 2025|Endpoints News|
Sarepta’s gene therapy vector wins FDA platform technology statusnews2025-06-04T19:49:13+00:00June 4th, 2025|Endpoints News|
